Organoids in Cancer Research – Paving the Way for Faster Drug Development Across Cancer Indications
- Showcasing HUB Organoids’ patient-derived organoid platform, highlighting biobank breadth, clinical annotation, and core PDO features such as genetic fidelity, phenotypic relevance, and assay versatility
- Demonstrating clinical validation through concordance between patient-derived organoid drug responses and patient outcomes, supporting the use of patient-derived organoids to de-risk and accelerate drug development
- Leveraging patient-derived organoids for immuno-oncology applications, integrating immune co-culture systems and functional assays to assess immunotherapy performance and inform target, indication and patient selection